

portion to enter the cytosol of the target cell and thence allow the peptide to exert [is] its [biological] immunomodulatory effect.

In claim 3, line 2, delete "an effective" and insert -- a --

~~Cancel~~ claim 4, without prejudice.

Rewrite claims 5, 7-14, 16 and 17 as follows:

A4 5(Amended). A polypeptide according to [any one of the preceding claims,] claim 1 or 2 wherein the cell surface component is an antigen or a receptor molecule.

A5 7(Amended). A polypeptide according to [any one of claims 4, 5 or 6, as dependent on] claim 1, wherein after internalisation the peptide is presented on the surface of the target cell in association with class II MHC antigen so as to modulate a T helper cell response.

8(Amended). A polypeptide according to [any one of the preceding claims,] claim 1 or 2 wherein the effector portion comprises one or more immunodominant T cell peptide epitopes.

sub 95 9(Amended). A polypeptide according to [any one of the preceding claims,] claim 1 or 2 wherein the effector portion comprises a number of repeats of the same peptide [capable of exerting] which exerts an immunomodulatory effect.

10(Amended). A polypeptide according to [any one of the preceding claims,] claim 1 or 2 wherein the effector portion comprises a plurality of different peptides, such that the

different peptides are capable of being presented by respective MHC antigens of a different haplotype.

11(Amended). A polypeptide according to [any one of the preceding claims,] claim 1 or 2 wherein the cell surface component is selected from the group consisting of: MHC class I antigen; MHC class II antigen; FcRI receptor; B cell surface immunoglobulin; Lewis Y antigen; TSH receptor; and the MBrl antigen.

a
5
12(Amended). A polypeptide according to [any one of the preceding claims,] claim 1 or 2 wherein the effector portion comprises a peptide unit(s) selected from the group consisting of: MAGE 1, 2 or 3 antigens; tetanus toxin P2 peptide; the HIV-V3 loop epitope; the p53 anti-oncogene protein; influenza virus matrix protein; and influenza virus nucleoprotein.

~~13(Amended). A polypeptide according to [any one of claims 4-12, as dependent on] claim 1, further comprising a signal directing the peptide unit(s) to a particular cellular compartment.~~

14(Amended). A polypeptide according to [any one of the preceding claims,] claim 1 or 2 comprising a translocation portion derived from the translocation domain of a bacterial exotoxin or HIV tat protein, or the endosome-disrupting function of an adenovirus.

a
6
16(Amended). A polypeptide according to [any one of the preceding claims,] claim 1 or 2 wherein the target cell is a "professional" antigen presenting cell (APC).

17(Amended). A polypeptide according to [any one claims 1 to 15,] claim 1 or 2 wherein the target cell is an aberrant, virus-infected or otherwise diseased cell.

Ab In claim 19, line 1, ~~delete~~ "17 or".

Rewrite claims 20 and 21 as follows:

20(Amended). A vaccine for stimulating an immune response, comprising an effective amount of a polypeptide in accordance with [any one of the preceding claims] claim 1 or 2, together with a physiologically acceptable carrier substance.

21(Amended). A method of modulating the immune response of a human or animal subject, comprising administering to the subject an effective amount of a polypeptide in accordance with [any one of claims 1 to 19] claim 1 or 2.

Add new ~~claim~~ 24 as follows:

24(New). A chimaeric polypeptide comprising::

- Ag
- (a) a binding portion comprising an anti-MHC immunoglobulin molecule expressed on APC target cells;
 - (b) an effector portion comprising p53 protein;
 - (c) a translocation domain of HIV tat protein; and
 - (d) a signal portion derived from translocation domain of pseudomonas exotoxin.

REMARKS

In accordance with the above-amendments, certain items were attended to in the specification to meet objections raised in paragraphs 2-5 raised by the Examiner. In addition, claims 1-3, 5, 7-14, 16, 17 and 19-22 have been amended and new claim 24 has